Teofila Seremet
Teofila Seremet
Dermatologist, Université Libre de Bruxelles, Belgium
Verified email at erasme.ulb.ac.be
Title
Cited by
Cited by
Year
Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases
A Cipponi, M Mercier, T Seremet, JF Baurain, I Théate, J van den Oord, ...
Cancer research 72 (16), 3997-4007, 2012
1692012
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm …
M Schreuer, Y Jansen, S Planken, I Chevolet, T Seremet, V Kruse, ...
The Lancet Oncology 18 (4), 464-472, 2017
1452017
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
M Schreuer, G Meersseman, S Van Den Herrewegen, Y Jansen, ...
Journal of translational medicine 14 (1), 1-11, 2016
1162016
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
YJL Jansen, EA Rozeman, R Mason, SM Goldinger, MHG Foppen, ...
Annals of Oncology 30 (7), 1154-1161, 2019
872019
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy
T Seremet, F Brasseur, PG Coulie
The Cancer Journal 17 (5), 325-330, 2011
372011
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, H El Housni, ...
Journal of translational medicine 17 (1), 1-13, 2019
362019
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib
YJ Jansen, P Janssens, A Hoorens, MS Schreuer, T Seremet, ...
Melanoma research 25 (6), 550-554, 2015
262015
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
T Seremet, A Koch, Y Jansen, M Schreuer, S Wilgenhof, V Del Marmol, ...
Journal of translational medicine 14 (1), 1-14, 2016
232016
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma
R Váraljai, K Wistuba-Hamprecht, T Seremet, JMS Diaz, J Nsengimana, ...
JCO Precision Oncology 3, 1-10, 2019
172019
Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma
N Sundahl, T Seremet, J Van Dorpe, B Neyns, L Ferdinande, A Meireson, ...
International Journal of Radiation Oncology* Biology* Physics 104 (4), 828-835, 2019
162019
Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
YJL Jansen, G Verset, K Schats, PJ Van Dam, T Seremet, M Kockx, ...
ESMO Open 4 (2), e000464, 2019
152019
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from …
T Seremet, S Planken, M Schreuer, Y Jansen, M Delaunoy, H El Housni, ...
Melanoma research 28 (1), 65-70, 2018
132018
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma
M Schreuer, G Meersseman, S van Den Herrewegen, Y Jansen, ...
Melanoma research 26 (2), 157-163, 2016
132016
Successful (neo) adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma
T Seremet, D Lienard, M Suppa, AL Trepant, S Rorive, E Woff, N Cuylits, ...
Melanoma research 25 (2), 180-183, 2015
122015
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma
T Seremet, S Planken, JK Schwarze, Y Jansen, L Vandeweerd, ...
Melanoma research 29 (1), 85-88, 2019
112019
Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition
G Awada, T Seremet, K Fostier, H Everaert, B Neyns
Blood advances 2 (16), 2156-2158, 2018
102018
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure
MS Schreuer, IL Chevolet, YJ Jansen, TC Seremet, S Wilgenhof, ...
Melanoma research 25 (1), 68-74, 2015
102015
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV …
Y Jansen, V Kruse, J Corthals, K Schats, PJ van Dam, T Seremet, ...
Cancer Immunology, Immunotherapy 69 (12), 2589-2598, 2020
62020
Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test
T Seremet, A Haccuria, D Lienard, V del Marmol, B Neyns
Melanoma research 29 (1), 95-98, 2019
62019
The predictive and prognostic significance of cell‐free DNA concentration in melanoma
R Váraljai, S Elouali, SS Lueong, K Wistuba‐Hamprecht, T Seremet, ...
Journal of the European Academy of Dermatology and Venereology 35 (2), 387-395, 2021
52021
The system can't perform the operation now. Try again later.
Articles 1–20